Healthcare

Mesoblast (ASX:MSB) has completed its first full year of commercial sales for RYONCIL, marking a transition from a development-stage biotechnology company towards a commercial cell therapy business.

Acrux Limited (ASX:ACR) has progressed its female testosterone development program while reporting higher customer receipts from its commercial portfolio. The company’s latest quarterly update provided further clarity on the regulatory pathway for its Hypoactive Sexual Desire Disorder (HSDD) treatment candidate and highlighted increased contributions …

Anatara Lifesciences (ASX:ANR) is exploring a potential opportunity in the growing metabolic health market through AOC, an orally administered anti-obesity candidate targeting weight regain following GLP-1 treatment.

Aroa Biosurgery (ASX:ARX) has gained greater visibility around the US reimbursement environment for skin-substitute products as it prepares to expand commercial activity for Symphony, its wound-care product.

Amplia Therapeutics (ASX:ATX) has expanded the development pathway for its lead oncology candidate narmafotinib through a clinical trial collaboration with Lilly.

Avecho Biotechnology (ASX:AVE) has progressed another important milestone in its Phase III cannabidiol (CBD) insomnia trial after an independent Data Monitoring Board recommended the study continue to full planned enrolment.

Healius (ASX:HLS) has spent the past year repositioning its business towards a more focused pathology model while addressing cost pressures and operational challenges. The company’s review of Agilex Biolabs, its clinical-trials laboratory division, forms part of this broader strategy.